Puma Biotechnology Inc (PBYI)
Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. Co. in-licenses from Pfizer, Inc., the global development and commercialization rights to PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Co. is primarily focused on the development and commercialization of the oral version of neratinib, and its drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers.
| Company Name: |
Puma Biotechnology Inc |
| Website: |
www.pumabiotechnology.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding PBYI: |
4 |
| Total Market Value Held by ETFs: |
$9.56M |
| Total Market Capitalization: |
$246.00M |
| % of Market Cap. Held by ETFs: |
3.88% |
|
|
April 20, 2024 • 1:01 AM Eastern
Hold (2.33 out of 4)
100th percentile
|
|
Free PBYI Email Alerts:
